192 related articles for article (PubMed ID: 30690902)
1. Influence of myopic macular degeneration severity on treatment outcomes with intravitreal aflibercept in the MYRROR study.
Cheung CMG; Ohno-Matsui K; Wong TY; Li T; Asmus F; Leal S;
Acta Ophthalmol; 2019 Aug; 97(5):e729-e735. PubMed ID: 30690902
[TBL] [Abstract][Full Text] [Related]
2. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
Lanzetta P; Cruess AF; Cohen SY; Slakter JS; Katz T; Sowade O; Zeitz O; Ahlers C; Mitchell P
Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal aflibercept for myopic choroidal neovascularization.
Pece A; Milani P
Graefes Arch Clin Exp Ophthalmol; 2016 Dec; 254(12):2327-2332. PubMed ID: 27286893
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.
Ikuno Y; Ohno-Matsui K; Wong TY; Korobelnik JF; Vitti R; Li T; Stemper B; Asmus F; Zeitz O; Ishibashi T;
Ophthalmology; 2015 Jun; 122(6):1220-7. PubMed ID: 25745875
[TBL] [Abstract][Full Text] [Related]
6. Is Choroidal or Scleral Thickness Related to Myopic Macular Degeneration?
Wong CW; Phua V; Lee SY; Wong TY; Cheung CM
Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):907-913. PubMed ID: 28166316
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K
Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration in a Clinical Setting.
Eleftheriadou M; Vazquez-Alfageme C; Citu CM; Crosby-Nwaobi R; Sivaprasad S; Hykin P; Hamilton RD; Patel PJ
Am J Ophthalmol; 2017 Feb; 174():160-168. PubMed ID: 27746298
[TBL] [Abstract][Full Text] [Related]
9. Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW.
Weber M; Dominguez M; Coscas F; Faure C; Baillif S; Kodjikian L; Cohen SY
BMC Ophthalmol; 2020 May; 20(1):206. PubMed ID: 32450838
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.
Matsumoto H; Hiroe T; Morimoto M; Mimura K; Ito A; Akiyama H
Jpn J Ophthalmol; 2018 Mar; 62(2):144-150. PubMed ID: 29411171
[TBL] [Abstract][Full Text] [Related]
11. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
[TBL] [Abstract][Full Text] [Related]
12. One-Year Outcomes of the Treat-and-Extend Approach with Aflibercept in Age-Related Macular Degeneration: Effects on Typical Choroidal Neovascularization and Retinal Angiomatous Proliferation.
Castro-Navarro V; Cervera-Taulet E; Montero-Hernández J; Navarro-Palop C
Ophthalmologica; 2016; 236(4):215-222. PubMed ID: 27997921
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
[TBL] [Abstract][Full Text] [Related]
14. Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration.
Sawada T; Wang X; Sawada O; Saishin Y; Ohji M
Clin Exp Ophthalmol; 2018 Jan; 46(1):46-53. PubMed ID: 28621038
[TBL] [Abstract][Full Text] [Related]
15. Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration: data from the INSIGHT study using the Swedish Macula Register.
Lövestam Adrian M; Vassilev ZP; Westborg I
Acta Ophthalmol; 2019 Feb; 97(1):91-98. PubMed ID: 30238648
[TBL] [Abstract][Full Text] [Related]
16. Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study.
Kim JH; Lee TG; Chang YS; Kim CG; Cho SW
Br J Ophthalmol; 2016 Dec; 100(12):1634-1639. PubMed ID: 26951770
[TBL] [Abstract][Full Text] [Related]
17. [Visual and anatomical outcomes of three intravitreal aflibercept injections in eyes with neovascular form of age-related macular degeneration].
Kałuiny JJ; Majer A; Jaworowska-Cieślińska I
Klin Oczna; 2015; 117(1):9-13. PubMed ID: 26349151
[TBL] [Abstract][Full Text] [Related]
18. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
19. Change in choroidal thickness after intravitreal aflibercept in pretreated and treatment-naive eyes for neovascular age-related macular degeneration.
Mazaraki K; Fassnacht-Riederle H; Blum R; Becker M; Michels S
Br J Ophthalmol; 2015 Oct; 99(10):1341-4. PubMed ID: 25877895
[TBL] [Abstract][Full Text] [Related]
20. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
Jørstad ØK; Faber RT; Moe MC
Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
